IL188442A0 - Compositions for affecting weight loss - Google Patents

Compositions for affecting weight loss

Info

Publication number
IL188442A0
IL188442A0 IL188442A IL18844207A IL188442A0 IL 188442 A0 IL188442 A0 IL 188442A0 IL 188442 A IL188442 A IL 188442A IL 18844207 A IL18844207 A IL 18844207A IL 188442 A0 IL188442 A0 IL 188442A0
Authority
IL
Israel
Prior art keywords
compositions
weight loss
affecting weight
affecting
loss
Prior art date
Application number
IL188442A
Other languages
English (en)
Original Assignee
Orexigen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orexigen Therapeutics Inc filed Critical Orexigen Therapeutics Inc
Publication of IL188442A0 publication Critical patent/IL188442A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL188442A 2005-07-27 2007-12-26 Compositions for affecting weight loss IL188442A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70287705P 2005-07-27 2005-07-27
PCT/US2006/028875 WO2007016108A1 (en) 2005-07-27 2006-07-24 Compositions for affecting weight loss

Publications (1)

Publication Number Publication Date
IL188442A0 true IL188442A0 (en) 2008-04-13

Family

ID=37198787

Family Applications (1)

Application Number Title Priority Date Filing Date
IL188442A IL188442A0 (en) 2005-07-27 2007-12-26 Compositions for affecting weight loss

Country Status (12)

Country Link
US (1) US20070117827A1 (https=)
EP (1) EP1907005A1 (https=)
JP (1) JP2009502931A (https=)
KR (1) KR20080042092A (https=)
CN (1) CN101237886A (https=)
AU (1) AU2006275914A1 (https=)
BR (1) BRPI0613911A2 (https=)
CA (1) CA2614539A1 (https=)
IL (1) IL188442A0 (https=)
MX (1) MX2008001136A (https=)
RU (1) RU2007147609A (https=)
WO (1) WO2007016108A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
HUE034290T2 (en) 2003-04-29 2018-02-28 Orexigen Therapeutics Inc Preparations containing opioid antagonist and bupropion to affect weight loss
CA2630624C (en) 2005-11-22 2013-08-06 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
KR20170077291A (ko) 2006-11-09 2017-07-05 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
TWI609702B (zh) 2006-11-09 2018-01-01 歐瑞根治療有限公司 層狀醫藥調配物
US8748448B2 (en) 2007-10-18 2014-06-10 Aiko Biotechnology Combination analgesic employing opioid agonist and neutral antagonist
JP2011500686A (ja) 2007-10-18 2011-01-06 アイコ バイオテクノロジー オピオイドと中性アンタゴニストを用いる組合せ鎮痛剤
WO2009143299A1 (en) 2008-05-20 2009-11-26 Neurogesx, Inc. Hepatoprotectant acetaminophen mutual prodrugs
JP2011521973A (ja) 2008-05-30 2011-07-28 オレキシジェン・セラピューティクス・インコーポレーテッド 内臓脂肪の状態を処置するための方法
ES2762113T3 (es) 2010-01-11 2020-05-22 Nalpropion Pharmaceuticals Inc Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor
SMT201700232T1 (it) 2010-12-03 2017-07-18 Orexigen Therapeutics Inc Aumento della biodisponibilita' farmacologica nella terapia con naltrexone
LT3730132T (lt) 2012-06-06 2022-08-25 Nalpropion Pharmaceuticals Llc Kompozicija, skirta panaudoti pacientų su didele širdies ir kraujagyslių ligų rizika antsvorio ir nutukimo gydymo būde
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
GB201704909D0 (en) * 2017-03-28 2017-05-10 Ldn Pharma Ltd Cancer therapy
GB201704911D0 (en) 2017-03-28 2017-05-10 Ldn Pharma Ltd High dose combo I
WO2018178690A1 (en) * 2017-03-28 2018-10-04 LDN Pharma Limited An agent that increases the expression of the bcl2-associated agonist of cell death for the treatment of cancer
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040024006A1 (en) * 1996-05-06 2004-02-05 Simon David Lew Opioid pharmaceutical compositions
HUE034290T2 (en) * 2003-04-29 2018-02-28 Orexigen Therapeutics Inc Preparations containing opioid antagonist and bupropion to affect weight loss

Also Published As

Publication number Publication date
US20070117827A1 (en) 2007-05-24
WO2007016108B1 (en) 2007-05-10
KR20080042092A (ko) 2008-05-14
EP1907005A1 (en) 2008-04-09
BRPI0613911A2 (pt) 2011-02-22
CA2614539A1 (en) 2007-02-08
AU2006275914A1 (en) 2007-02-08
RU2007147609A (ru) 2009-09-10
JP2009502931A (ja) 2009-01-29
CN101237886A (zh) 2008-08-06
MX2008001136A (es) 2008-03-13
WO2007016108A1 (en) 2007-02-08

Similar Documents

Publication Publication Date Title
IL188442A0 (en) Compositions for affecting weight loss
HUS2000015I1 (hu) Fungicid készítmények
IL178977A0 (en) Compositions for affecting weight loss
IL191572A0 (en) Pestcidal compositions
IL186721A0 (en) Bioenhanced compositions
GB0503337D0 (en) Compositions
GB0624290D0 (en) Novel compositions
IL187664A0 (en) Herbicidal compositions
ZA200705428B (en) Stable prostaglandin-containing compositions
IL186093A0 (en) Lignan-containing compositions
IL190321A0 (en) Compositions containing saratin
GB0607085D0 (en) Novel compositions
GB0526283D0 (en) Compositions
GB0501365D0 (en) Compositions
GB0524128D0 (en) Compositions
GB0502479D0 (en) Novel compositions
GB0502475D0 (en) Novel compositions
ZA200709913B (en) Bioenhanced compositions
GB0525321D0 (en) Novel compositions
GB0526282D0 (en) Compositions
GB0524803D0 (en) Novel compositions
GB0917779D0 (en) Novel compositions
GB0501364D0 (en) Compositions
GB0506065D0 (en) Compositions
GB0505758D0 (en) Novel compositions